A Phase 2, Open-Label Evaluation of the Safety and Efficacy of CB-10-01, Transgenic Lymphocyte Immunization (TLI) Against Telomerase, as Adjuvant Therapy in Subjects With Stage III Melanoma
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Stage IIIB Skin Melanoma
- Sponsor
- Cosmo Bioscience
- Enrollment
- 20
- Locations
- 5
- Primary Endpoint
- The primary efficacy endpoint will be the percentage of subjects who have no recurrence of metastatic melanoma at 24 months from the time of primary surgery.
- Last Updated
- 14 years ago
Overview
Brief Summary
The purpose of this study is to assess the safety, efficacy, and immunological response to the study product, TLI, as an adjuvant therapy in subjects with Stage III Melanoma.
Normal cells in the body have an established lifespan. Cancer cells on the other hand have the ability to continue to divide into new cells indefinitely. More than 85% of cancer has this ability because of an enzyme found in the cancer cell. The Investigational Product, Transgenic Lymphocyte Immunization (TLI), is aimed at helping the immune system target this enzyme found in most cancerous cells.
Subjects who meet all inclusion and exclusion criteria will undergo a leukapheresis in which white blood cells will be collected and used to manufacture their own personal study product. Subjects will receive 3 infusions of TLI roughly 1 month apart and will be followed over a 2 year period with routine laboratory draws, computed tomography (CT) scans and physical exams.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or female subjects ≥18 years of age and able to understand and give written informed consent
- •Women subjects of childbearing potential (WOCBP) and male subjects must be using an effective method of contraception
- •Histologic diagnosis of malignant melanoma:
- •Melanoma primary completely resected with negative margins. Primary surgery must be \<8 weeks from leukapheresis procedure
- •Stage IIIB or Stage IIIC according to the American Joint Committee on Cancer (AJCC) Tumor-Node-Metastasis (TNM) criteria (Appendix 2) OR previously resected Stage I or II melanoma that recurs as Stage IIIB or IIIC.
- •HLA-A2 positive
- •ECOG Performance Status of 0, 1 or 2 (Appendix 3)
- •Adequate bone marrow, hepatic, and renal function:
- •WBC ≥1500/μL
- •ANC ≥1000/μL
Exclusion Criteria
- •Female subjects, their partners and male subjects who are unwilling or unable to practice abstinence or use a barrier method (condoms) during intercourse to minimize the risk of exposure to the blood-borne transgene for the entire period of the study and for up to 8 weeks after the last TLI infusion
- •Known allergy to DMSO
- •Any malignancy from which the subject has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix
- •Primary ocular or mucosal melanoma
- •Autoimmune disease: subjects with a documented history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis \[scleroderma\], systemic lupus erythematosus, autoimmune vasculitis \[e.g., Wegener's granulomatosis\]) that has or may require systemic therapy
- •Concomitant therapy with any anticancer agent; immunosuppressive agents; other investigational therapies; or chronic use of systemic corticosteroids (used in the management of cancer or non cancer-related illnesses). Replacement doses of corticosteroids are allowed in subjects with adrenal insufficiency
- •Prior biologic therapy for melanoma
Outcomes
Primary Outcomes
The primary efficacy endpoint will be the percentage of subjects who have no recurrence of metastatic melanoma at 24 months from the time of primary surgery.
Time Frame: 24 months
Secondary Outcomes
- Percentage of subjects who have no recurrence of metastatic melanoma 9 and 16 months following the time of primary surgery.(9 and 16 months)